Physician profile
David Y Go
NPI 1962479212
$5,905.85
in general payments reported to CMS, 2019-2025
44 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $262 · 2021: $373 · 2022: $680 · 2023: $1,164 · 2024: $1,058 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.85 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $871.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $820.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $555.07 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $482.63 | 2019-2024 | Rexulti |
| Glaxosmithkline, LLC. | $424.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.60 | 2019-2025 | Xifaxan |
| Pfizer INC. | $222.87 | 2019-2025 | |
| Allergan, INC. | $212.72 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $201.28 | 2019-2023 | Qelbree |
| Amgen INC. | $192.20 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $160.65 | 2019-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $151.19 | 2021-2025 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $143.97 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $124.67 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $113.79 | 2022-2023 | Gvoke Hypopen |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.